Senhwa Biosciences, Inc. Report issue

For profit Phase 2
Founded: San Diego CA United States (2013)

Organization Overview

First Clinical Trial
2014
NCT02128282
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Chris Recknor, MD | Senhwa Biosciences | Senhwa Biosciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (4)

cisplatin (platinol) (1 trial)

cx 5461 (2 trials)

gemcitabine (gemzar) (1 trial)

silmitasertib (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Basal Cell (Phase 1)

Cholangiocarcinoma (Phase 2)

Coronavirus Infections (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 4